Skip to content

Safety and Efficacy of the Adapt Pericardial Patch in the repair of defects associated with congenital heart disease in participants aged between 1 and 12 years of age

A Pilot Study to evaluate Safety and Efficacy of the Adapt Pericardial Patch in the repair of defects associated with Congenital Heart Disease in participants aged between 1 and 12 years of age.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000308796
Enrollment
40
Registered
2013-03-20
Start date
2013-07-19
Completion date
2013-12-23
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

CardioCel is a new method to prepare and treat biological tissues used in human surgical procedures. This means that the tissue (here bovine pericardium) used to close or repair defects associated with congenital heart disease has not been approved for this purpose in Australia or in other parts of the world. This project is going to allow us to show if the CardioCel integrity is maintained. We believe the CardioCel to be equivalent to currently available patches used to repair congenital heart disease

Interventions

The Adapt Pericardial Patch (CardioCel) (4 x 4 cm) will be used for the repair of defects associated with Congenital Heart Disease. The research question is to assess whether the patch's integrity is maintained during follow-up (performation or aneurismal formation). CardioCel is comprised of tissue engineered bovine pericardium that is cross linked in diluted glutaraldehyde solution and treated with the ADAPT TEP technology. Only one size of CardioCel is available (4x4cm). CardioCel may be sutu

The Adapt Pericardial Patch (CardioCel) (4 x 4 cm) will be used for the repair of defects associated with Congenital Heart Disease. The research question is to assess whether the patch's integrity is maintained during follow-up (performation or aneurismal formation). CardioCel is comprised of tissue engineered bovine pericardium that is cross linked in diluted glutaraldehyde solution and treated with the ADAPT TEP technology. Only one size of CardioCel is available (4x4cm). CardioCel may be sutured or stapled in place. CardioCel is stored at room temperature, never below 5 degrees celcius or above 25 degrees celcius and away from direct heat source. The implant should not be re-sterilised. No extensive rinsing is required. The patch is immersed in sterile physiological saline to avoid dehydration of the patch prior to implantation. Implantation specifics will be determined at the time of surgery depending on the nature of the repair needed. In general, the surgeon may cut and shape CardioCel to suit the requirements of the procedure. Care needs to be taken when handling the device, for example by using atraumatic forceps, to avoid tearing or otherwise damaging the patch. The device needs to be examined for damage prior to implant. If one side of the patch appears smoother than the other, the device should be implanted with the smoother surface facing the blood flow surface. CardioCel may be cut, folded or layered as required. If layering, it is preferable to cut the material into separate sheets, creating edges rather than folding it, presenting the maximum number of cut surfaces to body tissue, to enhance penetration by cell and blood vessels. CardioCel may be sutured or stapled in place. It will hold sutures easily and firmly and will remain in situ whilst it is incorporated into surrounding tissues. Any unused pieces of CardioCel should be discarded. The solution in which the CardioCel is sterilised/stored should be disposed of using normal hospital chemical waste disposal methods. The surgical procedure time is dependent upon the severity of the condition being treated and any intra-operative complications that may occur. Routinely these type of procedures take approximately two hours.

Sponsors

A/Professor Christian Brizard
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
1 Days to 12 Years
Healthy volunteers
No

Inclusion criteria

1. Between the ages of 1 day and 12 years at the time or enrolment. 2. Has a congenital heart disease (including ventricular septal defect repair (VSD), atrial ventricular septal defect repair (VSD), atrio ventricular septal defects (AVSD) as determined by clinical assessment including echo cardiography and/or MRI 3. Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the subject's behalf. 4. Willing and able to complete all study visits and procedures

Exclusion criteria

1. Has a clinically confirmed infection 2. Has co-morbidities which are likely to lead to death within the study follow up period. 3. Is participating in another study. 4. Is likely to require additional surgical intervention using a bioprosthetic material. 5. Unwilling or unable to comply with treatment follow up requirements. 6. Any other clinical condition which leads the investigator to consider the subject unsuitable for enrolment into the study.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026